No se han encontrado actividades.
Información
- 3 Seguidores
- 3 Siguiendo
- 0 Pistas
- Masculino
- vínculos sociales
- Bio
-
Testosterone levels may start to decline after age 30 years in males and between ages 45 and 55 years in females. From the metabolic point of view, blood pressure, lipid profile, fasting glucose and hematocrit shall be monitored before and every 3 months on the 1st year of androgen therapy.8 Because testosterone can be aromatized in estradiol, its long-term effects on ovary, uterus and breast are not completely defined, thus screening for endometrial, ovarian, and breast cancer shall be performed in agreement with the particularities of each case. With the usual recommended therapeutic doses, amenorrhea will occur in 90% of the patients in the first 6 months, reaching almost 100% after 1 year of treatment.8 Although menstrual cycles are suspended, the endometrial evaluation in male transgenders has shown inconsistent results.
A second large RCT by Snyder et al.319 used the Functional Assessment of Chronic Illness Therapy-Fatigue scales (range 0-52) in 474 men treated with testosterone for 12 months. Furthermore, additional testing, such as parathyroid hormone, calcium, and vitamin D levels, may be required. Whether the changes in both these studies represent a clinically meaningful improvement is unclear. Study limitations included failure to report baseline erectile function, failure to identify a population of men with isolated ED, study population heterogeneity, and inconsistent inclusion criteria across studies. ED is one of the primary reasons that men seek testosterone treatment. Specifically, the AUA does not recommend routine PSA testing in men years of age unless they are at higher risk (e.g., positive family history, African American race), at which point decisions regarding PSA testing should be individualized.
The goals of this document are to (i) guide clinicians in how to assess patients for testosterone deficiency and manage them with testosterone products, and (ii) educate clinicians in key areas of testosterone in which many clinicians are deficient (e.g., interpreting the testosterone literature, understanding testosterone laboratory testing). The explosion in the use of testosterone in the past decade is multifactorial in its etiology, including the increased use of direct-to-consumer advertising, which has resulted in greater patient knowledge and demand; relaxation of the indications for testosterone prescribing by clinicians; and the establishment of clinical care centers devoted to men's health, testosterone treatment, and anti-aging strategies. Testosterone therapy should not be commenced for a period of three to six months in patients with a history of a cardiovascular events.
Improvements in sex drive were also assessed in another meta-analysis performed by Bolona et al.298 Using a variety of measures, the authors demonstrated improvement with a pooled effect of 1.31 (31% increase in sex drive) among men treated with testosterone, with greater improvements noted among men with lower baseline testosterone levels. A 2005 meta-analysis by Calof et al.190 pooled data from 19 RCTs to determine the number of all-cause prostate events in men who were on exogenous testosterone treatment compared to men who were on placebo. The Testim Registry in the United States followed PSA changes in men without prostate cancer who were on testosterone therapy.
The literature indicates that men with lower baseline testosterone levels are more likely to experience PSA level increases. In 2013, the AUA published the Early Detection of Prostate Cancer Guideline,222 which makes no specific statements about PSA screening in men with testosterone deficiency or in men on testosterone therapy. If the Hct exceeds 50%, clinicians should consider withholding testosterone therapy until the etiology of the high Hct is explained.187 While on testosterone therapy, a Hct ≥54% warrants intervention.
If you’re experiencing symptoms of low testosterone, it’s crucial to seek professional guidance to address these issues safely and effectively. In men, it’s diagnosed when levels fall below 300 nanograms per deciliter (ng/dL). Produced mainly in the testes in men and the ovaries in women, with a small amount made by the adrenal glands, its levels can significantly impact one’s quality of life. This increases the patient’s satisfaction with treatment and induces self-awareness for improvement in symptoms. However, symptoms such as changes in body composition, bone mineral density, lean body mass, muscle strength, etc., are difficult for the patient to appreciate immediately and require assessment of the treatment effects and feedback of the test results.
An exception can be made if patients do not have symptoms but have documented BMD loss. Testing intervals are the expert opinion of the Panel and are provided as a guide to aid clinicians in the follow-up of such patients. Please refer to Table 7 below for a summary of follow-up testing for men being treated for testosterone deficiency. Patients on short-acting IM or short-acting SQ pellets (testosterone cypionate or enanthate) should have their testosterone measured after several cycles such that testosterone level equilibration has been achieved.
While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. This document was written by the Evaluation and Management of Testosterone Deficiency Guideline Panel of the American Urological Association Education and Research, Inc., which was created in 2016. Other limitations included the possible subjective nature in reporting some adverse events. During the subsequent year of follow-up, eight men from the placebo group and one man who had been on treatment were adjudicated to have had a definite myocardial infarction. At the end of the year-long treatment period, two men from the treatment arm had a definite myocardial infarction, and none were recorded in the placebo arm.
One strategy is to further evaluate patients using adjunctive tests, which might strengthen an argument for a short-term trial of testosterone therapy. The Panel urges clinicians to use their clinical judgment in the management of such patients. Given that the direct method for free testosterone measurement is also time-consuming and labor intensive, calculation derived free testosterone measurement is more commonly used, however there is considerable variation in total testosterone assays as well as the clinical conditions that affect serum albumin and SHBG, all of which impact this measurement. The Panel recommends that clinicians use the same laboratory with the same method/instrumentation for serial total testosterone measurement. Establishing total testosterone thresholds for a diagnosis of testosterone deficiency is challenging considering the heterogeneity that exists in the testosterone deficiency literature. However, as the testosterone literature uses absolute values to define low testosterone, the absolute value is ultimately the most important factor to determine whether patients may expect to achieve benefits with testosterone therapy. Evidence strength refers to the body of evidence available for a particular question and includes not only individual study quality but consideration of study design, consistency of findings across studies, adequacy of sample sizes, and generalizability of samples, settings, and treatments for the purposes of the guideline. - https://jobs-max.com/employer/steroids-vs-natural-bodybuilding-how-to-spot-a-fake-natty-easily/
Artistas a seguir
Top pistas semanales
© 2026 Myanmar Music Portal